Cancer Research Meeting Calendar Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanno, H.
Right arrow Articles by U, H.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanno, H.
Right arrow Articles by U, H.-S.
[Cancer Research 60, 2820-2824, June 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Role of the von Hippel-Lindau Tumor Suppressor Protein during Neuronal Differentiation

Hiroshi Kanno1, Farid Saljooque, Isao Yamamoto, Satoshi Hattori, Masahiro Yao, Taro Shuin and Hoi-Sang U

Division of Neurosurgery, Veterans Administration San Diego Healthcare System, University of California San Diego, San Diego, California 92161 [H. K., F. S., H-S. U.]; Departments of Neurosurgery [H. K., I. Y.], Urology [M. Y.], and Anesthesiology [S. H.], Yokohama City University School of Medicine, Yokohama 236-0004, Japan; and Department of Urology, Kochi Medical School, Nangoku-shi 783-8505, Japan [T. S.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
The von Hippel-Lindau (VHL) tumor suppressor protein down-regulates transcription by transcriptional elongation enhanced by antagonizing elongin B and C. Transcriptional regulation is an important control mechanism for embryogenesis and tumorigenesis. The VHL gene and protein are expressed in neuronal cells of the fetal and adult brain. However, the role of the VHL gene in the central nervous system (CNS) has not been elucidated. The VHL gene might modify the expression of various genes during embryogenesis and tumorigenesis in CNS. We investigated the role of the VHL gene in CNS development using rodent CNS progenitor cells. Here we show that expression of the VHL protein is correlated with neuronal differentiation but not with glial differentiation in CNS progenitor cells, and we also show that VHL gene transduction induces neuronal differentiation. In addition, a VHL mRNA antisense oligonucleotide inhibits differentiation of CNS progenitor cells and up-regulates their cell cycle. In conclusion, the VHL gene plays an essential role in neuronal differentiation as well as transcription.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Germ-line mutations of the VHL2 tumor suppressor gene (1) constitute a predisposition to the development of retinal angiomas, CNS hemangioblastomas, renal cell carcinomas, and pheochromocytomas. Loss or inactivation of the remaining wild-type allele is required for tumor development in VHL disease. In addition, somatic mutations of the VHL gene are frequently detected in sporadic renal cell carcinomas (2) and hemangioblastomas (3) , and somatic inactivation of both VHL alleles is a critical step in the pathogenesis of sporadic renal cell carcinoma and hemangioblastomas. Despite the positional cloning of the VHL gene (1) , the function of the VHL gene is not well defined. However, because abnormalities of this gene are occasionally associated with transformation of cells in the nervous system (4) , it is possible that the normal function of the VHL gene is involvement in CNS development.

Elongin B and C bind to elongin A to form a heterotrimeric transcription factor. This complex increases RNA transcription by the suppression of polymerase II pausing. A frequently mutated region of the pVHL can bind to complexes containing elongin B, elongin C (5) , and Clu-2 (6) . In so doing, pVHL suppresses transcriptional elongation of mRNA and reduces the transcription of target genes. Kessler et al. (7) demonstrated ubiquitous VHL gene expression during mouse embryogenesis. Richards et al. (8) investigated the expression of VHL mRNA during human embryogenesis, and strong expression was found in the CNS, kidneys, testis, and lung. They hypothesized that VHL-mediated control of transcriptional elongation might have an important role in normal development, including CNS development. This relationship between the VHL gene and cellular differentiation is supported by findings with other tumor suppressor genes. Neuronal morphological change in PC-12 cells is associated with up-regulation of the colorectal cancer (DCC) gene, which is involved in a distal segment of neuronal differentiation (9) . The adenomatous polyposis coli (APC) gene protein is also up-regulated in association with neuronal differentiation (10) . The retinoblastoma gene product (pRb) plays an important role not only in controlling entry into the cell cycle, it is also involved in the distal differentiation of many different cell types (11) . The expression of tuberous sclerosis gene 2 (TSC2) is up-regulated on induction of neuronal differentiation at the posttranscriptional level (12) . In contrast, both p53 and p21 block neuronal differentiation, and suppression of p53 and p21 induces neuronal differentiation (13 , 14) . In terminal neuronal differentiation, basic helix-loop-helix transcriptional factors such as MASH-1 (15) , NeuroD (16) , NeuroD-related factor, and HES-1 (17) also play critical roles. Recently SOX-1, a HMG-box protein related to SRY, was shown to be one of the earliest transcription factors involved in an embryogenic stage transition from ectodermal cells to neural fate (18) .

Pluripotential neural progenitor cells demonstrate the ability to differentiate over time when exposed to the appropriate environmental signals. These progenitor cells eventually give rise to the full complement of cell types found in the mature brain and spinal cord (19) CNS stem cells, which exist in embryonic (20) and adult brains (21) . During the course of cellular differentiation, cell type-specific antigens are expressed at specific times. Nestin, a marker for CNS stem cells (22) , is expressed early, when cells are presumed to possess pluripotentiality. Recently, it has been reported that POU transcription factors bound by the enhancer of nestin control expression of the nestin gene (23) . The progressive expression of GFAP, a marker for astrocytes (24) , is considered to represent glial differentiation of CNS stem cells. On the other hand, MAP-2, a marker for neurons (25) , is expressed along with neuronal differentiation. The VHL gene and protein are expressed in neuronal cells in the fetal and adult CNS (6 , 7 , 26) . However, the relationship between the differentiation of neuron or glia from CNS stem cells and the function of the VHL gene is not well defined.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Progenitor Cell Culture.
Embryonic E12 fetuses were obtained from anesthetized pregnant Sprague-Dawley rats (Harlan, San Diego, CA). Tissues from the forebrain and hindbrain were dissected, digested with 0.05% trypsin (Life Technologies, Inc.) and 0.02% ethylenediamine tetraacetic acid (Life Technologies, Inc.) at 37°C for 10 min, dissociated by gentle trituration in DMEM (Life Technologies, Inc.) and 10% (FCS Life Technologies, Inc.), and filtered through a sterile 60-mesh membrane. Cells in suspension were plated onto poly-L-ornithine-coated coverslips in DMEM and 10% FCS at a concentration of 106 cells/35-mm culture dish. After 24 h, the medium was changed to serum-free DMEM/F12 (1:1; Life Technologies, Inc.) supplemented with glucose (0.6%), glutamine (2 mM), NaHCO3 (3 mM), insulin (25 µg/ml), transferrin (100 µg/ml), progesterone (20 mM), putrescine (60 µM), selenium chloride (30 mM), and HEPES buffer (pH 7.4), as described previously (27) . EGF and bFGF were added either alone or in combination at concentrations of 10-11 and 10-9 M, respectively. Serum-free medium was substituted at 24 h to define the conditions that promote optimum cell survival and differentiation.

Immunocytochemical Studies.
Cells on coverslips were fixed for 30 s in cold acetone (4°C), cooled quickly in a deep freezer (-70°C), and maintained at -70°C until the study. On days 1, 5, and 14, the cells were blocked with 5% NGS in PBS and exposed to one of the following primary antibodies for 60 min at 37°C: (a) a mouse mAb specific for MAP-2 (1:100; Sigma); (b) a rabbit polyclonal antibody (pAb) specific for GFAP (1:100; Sigma); (c) a mouse mAb specific for nestin (1:100; PharMingen); (d) mouse mAb VHL40 (28) , specific for pVHL (1:100; kindly provided by Dr. N. Sakashita; Department of Pathology, Kumamoto University School of Medicine, Kumamoto, Japan). Controls consisted of staining with 5% NGS in PBS from which the primary antibody was omitted. Secondary antibody staining consisted of exposure to swine antimouse or antirabbit immunoglobulin conjugated to rhodamine (1:40) for 30 min at 37°C. Coverslips were mounted onto slides and viewed. Expression of marker proteins was evaluated by fluorescence immunocytochemical study with a positive rate in cultured rodent progenitor cells.

Double Immunocytochemical Study.
Cells on coverslips were washed with PBS before fixation with acetone for 30 s, cooled quickly, and maintained at -70°C until the study. After exposure to 0.5% Triton X-100 in PBS for 10 min, the cells were treated with blocking buffer (5% NGS in PBS) for 30 min at room temperature. The cells were then exposed to an antibody mixture composed of: (a) a rabbit pAb specific for GFAP (1:100; Sigma) or MAPs (1:100; Sigma) diluted in PBS; and (b) mouse mAb VHL40 (1:100) in PBS. Controls consisted of staining of staining with 5% nonimmune NGS. After a reaction of 1 h at 37°C, the cells were washed extensively with 0.075% Tween 20 in PBS. Reaction was then undertaken with a second antibody mixture composed of: (a) a goat antirabbit immunoglobulin conjugated to rhodamine (1:30; Sigma) in PBS; and (b) a goat antimouse immunoglobulin conjugated to fluorescence (1:30; Cappel, West Chester, PA) in PBS. After a reaction for 30 min at 37°C, stained cultures were washed extensively with 0.075% Tween 20 in PBS and mounted for fluorescence microscopy. A laser scanning confocal microscope (Zeis, Germany) was used for observation of double-stained cells.

Western Blotting.
Cultured cells were washed twice with PBS and homogenized in a lysis buffer (0.1 mol/liter NaCl, 0.01 mol/liter Tris-HCL, 0.01 mol/liter EDTA, and 1 µg/ml aprotinin). Assays to determine the protein concentration of the lysate were subsequently performed by comparison with known concentrations of bovine serum albumin. SDS-gel electrophoresis was performed in 12% polyacrylamide gels under nonreducing conditions. Lysates equivalent to 15 µg of protein were electrophoresed on each gel, together with prestained molecular weight markers (Sigma). The electrophoresis running buffer contained 25 mmol/liter Tris base, 250 mmol/liter glycine, and 0.1% SDS (pH 8.3). Proteins on the gel were subsequently transferred to a nitrocellulose transfer membrane (Sigma) in transfer buffer containing 25 mmol/liter Tris base, 250 mmol/liter glycine, and 20% methanol (pH 8.3). The membrane was placed in 5% skim milk in 25 mmol/liter Tris-buffered saline for 1 h to block nonspecific binding. The membrane was then incubated with the following primary antibodies for 60 min at 37°C: (a) a mouse mAb specific for MAP-2 (1:100; Sigma); (b) a rabbit pAb specific for GFAP (1:100; Sigma); (c) a mouse mAb specific for nestin (1:100; PharMingen); and (d) mouse mAb VHL40. The dilution solution was TBS-T [50 mmol/liter Tris-HCL (pH 7.6), 150 ml of NaCl, and 0.05% Tween 20]. After thorough washing with TBS-T, biotinylated antimouse IgG (1:400; Vector Laboratories, Burlingame, CA) or biotinylated antirabbit IgG (1:400; Sigma) was applied for 60 min. An additional series of washes was followed by incubation with biotin-streptavidin complex conjugated with horseradish peroxidase (1:400; Vector Laboratories). Proteins were detected with diaminobenzidine tetrahydrochloride (Sigma). Membranes were finally washed in distilled water and air dried.

Labeling with BrdUrd.
Bromodexyuridine (Sigma) was added at 10 mM to progenitor cell cultures 24 h before fixation. Cells were washed with PBS, fixed in cold acetone, and preserved at -70°C until the study. After incubation with 2 M HCl, washing with borate buffer (pH 9), and blocking with 0.1% Triton X-100 in 2% NGS, primary mAb to BrdUrd (1:100; DAKO) was added for 60 min at 37°C. The secondary antibody was a rabbit antimouse immunoglobulin conjugated to biotin (1:100; Sigma), which was added for 30 min at 37°C. The third antibody was avidin-biotin complex conjugated to horseradish peroxidase (1:100; Vector Laboratories), which was added for 30 min at 37°C. The reaction was initiated with 0.02% diaminobenzidine tetrahydrochloride (Sigma) and 0.02% superoxide in distilled water. Coverslips were mounted onto slides and viewed.

VHL Gene Transduction.
VHL cDNA was amplified with the PCR method. The primers used were as follows: (a) forward, 5'-CTGAATTCACCATGGAGGCCGGGCGGCCG-3'; and (b) backward, 5'-GAGAATTCTCAATCTCCCATCCGTTGATG-3'. A defective herpes simplex virus vector expressing pVHL (dvHSV/VHL) was generated as described previously (29) . The VHL gene was driven by the cytomegalovirus immediate early promoter. Amino acids 54-213 of pVHL were expressed with transfection of dvHSV/VHL. The VHL gene transduction into rodent progenitor cells was performed with 1 x 106 plaque-forming units of dvHSV/VHL at day 1. As the control vector, a defective herpes simplex virus vector containing the bacterial LacZ gene was used, with the same plaque-forming units. Expressions of pVHL and MAP-2 were examined using the fluorescence immunocytochemical study.

VHL mRNA Antisense Oligonucleotide Study.
Antisense oligonucleotides against rodent VHL mRNA were designed by Dr. K. Uchida (Toagosei Co., Ltd., Tsukuba Research Laboratory, Tsukuba, Japan) from mRNA regions having low tendencies to form an intramolecular double-stranded structure. A control oligonucleotide was randomly designed to be composed of the same ratio of each base. The two antisense oligonucleotides (patents pending in Japan and the United States) were A617T (5'-CGAGGTGCTCTTGGGTCAGC-3') and A853T (5'-GAAAGGGCAGACTCGGTGGC-3').

The control oligonucleotide was 5'-GACAACGAGTCTGACGTTTC-3'

Rodent CNS stem cells were obtained from E12 pregnant rats and cultured as described previously (27) . VHL mRNA antisense or control oligonucleotide was added at 1 µM in serum-free media containing N2 and bFGF. To investigate the effects of VHL mRNA antisense oligonucleotides on the differentiation of CNS stem cells, expression of pVHL, GFAP, MAPs, and nestin on day 10 was examined with immunocytochemistry. In addition, the proliferative abilities on day 1 and day 5 were evaluated with the BrdUrd index.

Statistical Analysis.
The rate of the immunoreactive cells was determined as the percentage of positively stained cells per random 400 cells counted, which was then normalized to 100. Comparison of each group was made using Student’s t test. Statistical significance was set at the level of P < 0.05.

Approval of the Animal Study.
This study was approved by our institutional animal care and use committees.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
When cultures were exposed to serum-free medium supplemented with N2 (Life Technologies, Inc.) and bFGF (Life Technologies, Inc.), progressive stereotypic development of cell type-specific markers was observed. On initial plating (day 1), cultured cells from embryonic E12 fetuses of Sprangue-Dawley rats assumed a small round shape with short processes, consistent with their identity as progenitor cells. This was confirmed by positive immunostaining for nestin, an intermediate filament present in pluripotential CNS progenitor cells. At the same time, staining for MAP-2, a maker for neurons, or GFAP, a marker for astrocytes, was rarely observed, whereas staining for pVHL was detected in the nucleus of some cells. With progressive culture, the cell soma increased in size and developed elongated processes, consistent with the attainment of a more mature phenotype. Starting from 5 days after primary culture (day 5), the number of GFAP-positive cells increased, whereas the expression of MAP-2 and VHL was also increased (data not shown). A decline in nestin expression occurred concomitantly with the increase in MAP-2, pVHL, and GFAP expression at day 14. By day 60, nestin immunoreactivity was barely detectable. Together, these data indicate that the cultured E12 cells were behaving as pluripotential stem cells, differentiating over time into cells demonstrating neuronal and glial properties. When the serum-free medium was supplemented with N2 and EGF, cells preferentially developed GFAP immunoreactivity, and MAP-2- or pVHL-positive cells were rarely seen at day 14. These data indicated that EGF selectively induced glial marker expression (Fig. 1Citation ).



View larger version (36K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expressions of cell-specific marker protein in cultures of rodent neural progenitor cells at day 1 and day 14 treated with bFGF or EGF. Bar graphs show the ratios of positive cells with fluorescence immunocytochemical study. The percentage of positive cells was calculated based on a count of 1000 cultured progenitor cells. Expression of the nestin decreased for either bFGF or EGF treatment. There is a significant difference (P < 0.01) between bFGF and EGF treatments. Expression of GFAP increased with bFGF or EGF treatment. The ratio of GFAP-positive progenitor cells was significantly higher with EGF treatment than with bFGF treatment (P < 0.01). Expressions of MAP-2 and pVHL increased for either bFGF or EGF treatment. There is no significant increase in the positive proportion of MAP-2 or pVHL reactivity at day 14. Day 1, one day after the primary culture of E12 neural progenitor cells. Day 14, 14 days after the primary culture of E12 neural progenitor cells. *, P < 0.05; **, P < 0.01.

 
To identify pVHL-positive cells, a double immunocytochemical study was performed using a laser scanning confocal microscope. On day 14, coexpressions of MAPs and pVHL were detected in the same cells, whereas expressions of GFAP and pVHL were detected in different cells (Fig. 2Citation ). MAPs were detected distinctly in the perinuclear cytoplasm and dendrites as well as in the nucleus, whereas expression of pVHL was detected in both the nucleus and cytoplasm. The pVHL staining in the cytoplasm was more distinct than that in the nucleus. The staining was scarcely observed in the dendrites. The double immunocytochemical studies on cultured embryonic rodent cells at day 14 revealed that MAP-positive cells were identified as pVHL positive.



View larger version (39K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Double fluorescence immunocytochemical study on CNS progenitor cells at day 14 using a laser scanning confocal microscope. A, coexpression of pVHL and MAP is found at the same CNS progenitor cells. pVHL is detected with FITC (green), and MAPs are detected with rhodamine (red). B, expressions of pVHL and GFAP are found in different CNS progenitor cells. pVHL is detected with FITC (green), and GFAP is detected with rhodamine (red). Scale bar, 10 µm.

 
Western blotting studies revealed that lysates of the cultured embryonic rodent cells on day 1 showed a distinct expression of nestin, a distinct expression of VHL protein on day 1, and a weak expression of MAP-2 on day 14, but no expression of GFAP. Lysates of the cells cultured with bFGF on day 14 showed potent expressions of GFAP, MAP-2, and VHL proteins but had a reduced expression of nestin. On the other hand, lysates of the cells cultured with EGF on day 14 showed potent expression of GFAP but little expression of MAP-2 and pVHL and a more reduced expression of nestin than cells cultured on days 1 and 14 with bFGF (Fig. 3Citation ). These data were supported by the fluorescence immunocytochemical studies on cell-specific proteins of CNS progenitor cells.



View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Western blot analysis of cell-specific marker proteins in cultures of rodent neural progenitor cells at day 1 and day 14 treated with bFGF or EGF. Cell lysates from neural progenitor cells were blotted with antibodies to nestin, pVHL, and GFAP that recognized appropriate bands at Mr 200,000, Mr 19,000, and Mr 52,000, respectively. The blots probed with an antibody to MAP-2 were shown as two appropriate bands, one at Mr 280,000 corresponding to MAP-2a and MAP-2b, and one at Mr 70,000 corresponding to MAP-2c. Expressions of nestin and pVHL at day 1 (one day after the primary culture) are distinctly detected. Expressions of MAP-2, GFAP, nestin, and pVHL are distinctly detected at day 14 with bFGF treatment, whereas expressions of pVHL and MAP-2 disappeared at day 14 with EGF treatment.

 
The effect of VHL gene transduction was examined at 3, 6, 24, 48, 72, 120, and 168 h after the transduction. Significant expressions of pVHL and MAP-2 were observed at 3 and 24 h after the transduction, respectively. The expression rate of pVHL was significantly higher than that of MAP-2 at 3 and 6 h after VHL gene transduction. The pVHL expression was shown earlier than that of MAP-2. In addition, both expressions were observed significantly earlier than the control (P < 0.0001). These results revealed that VHL gene transduction into neural progenitor cells induced rapid neuronal differentiation (Fig. 4Citation ).



View larger version (29K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Effects of VHL gene transduction on neural progenitor cells. A, expressions of pVHL and MAP-2 after the VHL gene transduction. Significant expressions of pVHL and MAP-2 were observed at 3 and 24 h after the transduction, respectively. The expression rate of pVHL was significantly higher than that of MAP-2 at 3 and 6 h after VHL gene transduction (P < 0.001). In addition, both expressions were observed significantly earlier than the control (P < 0.0001). B, expressions of pVHL and MAP-2 after bacterial LacZ gene transduction. {blacksquare}, pVHL; {blacksquare}, MAP2.

 
The effect of VHL mRNA antisense oligonucleotides on marker expression was examined with expressions of nestin, MAP-2, VHL, and GFAP proteins on day 10. The study with the control oligonucleotide revealed that the protein expression pattern was similar to that observed in cells without exposure to the oligonucleotide. The proportions of nestin and GFAP-positive cells (positive cells/all cells in the random 400 cells counted) with the control oligonucleotide were 24.2 ± 3.4% and 15.7 ± 2.9%, respectively. In addition, the proportions of MAP-2- and pVHL-positive cells were 60.1 ± 5.4% and 72.0 ± 5.3%, respectively. The protein expression pattern with VHL mRNA antisense oligonucleotide A852T was similar to that seen using the control oligonucleotide. On the other hand, the protein expression with VHL mRNA antisense oligonucleotide A617T showed a pattern different from those seen using the control oligonucleotide or the A852T antisense oligonucleotide. The expressions of nestin (37.9 ± 4.7%) and GFAP (20.1 ± 3.6%) were at higher levels than those seen when cells were exposed to the control oligonucleotide or antisense A852T oligonucleotide. In contrast, the expressions of MAP-2 (8.0 ± 2.0%) and pVHL (8.3 ± 1.7%) were suppressed. These immunocytochemical results revealed that VHL mRNA antisense oligonucleotide A617T suppressed the expression of neuronal markers. In addition, the BrdUrd labeling index on days 1, 5, and 9 was examined. The BrdUrd index of rodent E12 culture cells treated with A617T was significantly higher (P < 0.001) than those of nontreated cells, cells treated with the control oligonucleotide, and cells treated with A852T on days 1 and 5. These results suggest that inhibition of neuronal markers with VHL mRNA antisense oligonucleotide A617T promoted transition of the cell cycle of rodent progenitor cells. The protein expression pattern was similar to the expression pattern with serum-free culture medium containing EGF, but the nestin expression showed higher than the culture with EGF (Fig. 5Citation ).



View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Effects of VHL mRNA antisense oligonucleotides on neural progenitor cells. A, expression of cell-specific marker proteins at day 10. A617T showed significantly lower positive cell proportions of both MAP-2 and pVHL antibodies than A852T (P < 0.001) or the control oligonucleotide (P < 0.0001). Positive cell proportion of the nestin reactivity in cells treated with A617 was significantly higher than that in cells treated with A852T (P < 0.05) or the control oligonucleotide (P < 0.05). There are no significant differences in GFAP reactivity among cells treated with A617T and A852T and cells treated with the control oligonucleotide treatment. B, BrdUrd labeling index of neural progenitor cells treated with or without A617T, A852T, and the control oligonucleotide at day 1 and day 5. BrdUrd indexes of neural progenitor cells increased over time under all conditions. BrdUrd labeling index of cells treated with A617T was significantly higher than the labeling index of cells treated with A852T, the control oligonucleotide, or no treatment at day 1 (P < 0.01) and at day 5 (P < 0.05). *, P < 0.05; **, P < 0.01.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Expression of pVHL was progressively observed in cultured CNS progenitor cells. pVHL was initially undetectable in freshly harvested E12 cells, which were mostly nestin positive. By day 5 and day 14, pVHL expression was increasingly evident. In addition, pVHL expression was correlated with expression of MAP-2, a neuronal marker. Double immunocytochemistry revealed that pVHL and MAPs were expressed in the same cells. High-power observation, however, revealed that pVHL expression was shown in the nucleus and the cytoplasm, whereas MAP expression was shown in the cytoplasm and the dendrites. Their expression in the same cell type suggested that the VHL gene might be involved in neuronal differentiation from CNS stem cells. In addition, the present VHL gene transduction study revealed that the VHL gene induced neuronal differentiation. In contrast, the VHL mRNA antisense oligonucleotide study revealed that suppression of the VHL gene inhibited neuronal differentiation and promoted cell cycle transition in rodent E12 cultured progenitor cells. These results suggest that the VHL gene plays an essential role not only in neuronal differentiation but also in the proliferative state of CNS development. Because VHL modulates transcription, it may modulate CNS development through its effects on the transcription of developmentally related genes. This is similar to other tumor suppressor genes such as Rb (10) , TSC2 (11) , APC (9) , and DCC (8) , which are also implicated in neuronal differentiation at the posttranscriptional state. The Rb gene is implicated in neuronal differentiation, probably through its effects on gene transcription (10) . The Rb gene product is detected in normal retinal nerve cells, but its expression in CNS neuron has not been demonstrated. The expression of the TSC2 gene product is identified in cerebral and cerebellar nerve cells, and the TSC2 gene plays a role in distal-neuronal differentiation. On the other hand, VHL mRNAs and the VHL gene product are readily demonstrated in CNS neurons (7 , 8 , 26) . These observations and the results from the present study suggest that the VHL gene plays an important role in neuronal differentiation, probably through its effects on gene transcription. In this regard, the VHL gene product is similar to the proneural gene product, a basic helix loop-helix transcription factor (30) , which is essential for neuronal differentiation in CNS development.

In clinical application of CNS stem cells, VHL mRNA antisense oligonucleotide, which inhibits differentiation of CNS stem cells, may be useful to maintain CNS stem cells for transplantation to CNS.


   Acknowledgments
 
We thank Dr. N. Sakashita and Dr. M. Takeya (Department of Pathology, Kumamoto University School of Medicine, Kumamoto, Japan) for providing anti-pVHL monoclonal antibody, and we also thank Dr. S. Kawamoto (Department of Microbiology, Yokohama City University, Yokohama, Japan) for advice and Dr. K. Uchida (Toagosei Co., Ltd., Tsukuba Research Laboratory, Tokyo, Japan) for designing antisense oligonucleotides targeting sites on VHL mRNA.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Department of Neurosurgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Phone: 81-45-787-2663; Fax: 81-45-783-6121; E-mail: kanno{at}med.yokohama-cu.ac.jp Back

2 The abbreviations used are: VHL, von Hippel-Lindau; CNS, central nervous system; pVHL, VHL protein; GFAP, glial fibrillary acidic protein; MAP, microtubule-associated protein; NGS, normal goat serum; mAb, monoclonal antibody; pAb, polyclonal antibody; bFGF, basic fibroblast growth factor; BrdUrd, bromodeoxyuridine; EGF, epidermal growth factor. Back

Received 11/ 4/99. Accepted 4/14/00.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Latif F., Gnarra J., Tory K., Yao M., Duh F-M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L., Schmidt L., Zhou F., Li H., Wei M. H., Chen F., Glenn G., Choyke P., Walter M. M., Weng Y., Duan D. R., Dean M., Glavac D., Richards F. M., Crossey P. A., Ferguson-Smith M. A., Paslier D. L., Chumkov I., Cohen D., Chinault C., Mahler E. R., Linehan W. M., Zbar B., Lerman M. I. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (Washington DC), 260: 1317-1320, 1993.[Abstract/Free Full Text]
  2. Shuin T., Kondo K., Torigoe S., Kishida T., Hosaka M., Nagashima Y., Kitamura H., Latif F., Zbar B., Lerman M. I., Yao M. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinoma. Cancer Res., 54: 2852-2855, 1994.[Abstract/Free Full Text]
  3. Kanno H., Kondo K., Ito S., Yamamoto I., Fujii S., Torigoe S., Sakai N., Hosaka M., Shuin T., Yao M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res., 54: 4845-4847, 1994.[Abstract/Free Full Text]
  4. Kanno H., Shuin T., Kondo K., Yamamoto I., Ito S., Shinonaga M., Yoshida M., Yao M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res., 57: 1035-1038, 1997.[Abstract/Free Full Text]
  5. Duan D. R., Pause A., Burgess W. H., Aso T., Chen D. Y. T., Garret K. P., Conaway J. W., Linehan W. M., Klauser R. D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (Washington DC), 269: 1402-1406, 1995.[Abstract/Free Full Text]
  6. Pause A., Lee S., Worrell R. A., Chen D. Y., Burgess W. M., Klausner R. D. The von Hippel-Lindau tumor suppressor gene product forms a stable complex with human CUL-2, a member of the cdc 53 family of proteins. Proc. Natl. Acad. Sci. USA, 94: 2156-2161, 1997.[Abstract/Free Full Text]
  7. Kessler P. M., Vasavada S. P., Rackley R. R., Stackhouse T., Duh F-M., Latif F., Lerman M. I. Expression of the von Hippel-Lindau tumor suppressor gene in human fetal kidney and during mouse embryogenesis. Mol. Med., 1: 457-466, 1995.[Medline]
  8. Richards F. M., Schofield P. N., Fleming S., Maher E. R. Expression of the von Hippel-Lindau disease tumor suppressor gene during human embryogenesis. Hum. Mol. Genet., 5: 639-644, 1996.[Abstract/Free Full Text]
  9. Lawlor K. G., Narayanan R. Persistent expression of the tumor suppressor gene DCC is essential for neuronal differentiation. Cell Growth Differ., 3: 609-616, 1992.[Abstract]
  10. Dobashi Y., Bhattacharjee R. N., Toyoshima K., Akiyama T. Upregulation of the APC gene product during neuronal differentiation of rat pheochromocytoma PC12 cells. Biochem. Biophys. Res. Commun., 224: 479-483, 1996.[Medline]
  11. Lee E. Y., Hu N., Yuan S. S., Cox L. A., Bradley A., Lee W. H., Herrup K. Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation. Genes Dev., 8: 2008-2021, 1994.[Abstract/Free Full Text]
  12. Soucek T., Hotzl G., Bernaschek G., Hengstschlager M. A role of the tuberous sclerosis gene-2 product during neuronal differentiation. Oncogene, 16: 2197-2204, 1998.[Medline]
  13. Poluha W., Schonhoff C. M., Harrington K. S., Lachaynkar M. B., Crosbie N. E., Bulseco D. A., Ross A. H. A novel, nerve growth factor-activated pathway involving nitric oxide, p53, and p21WAF1 regulates neuronal differentiation of PC12 cells. J. Biol. Chem., 272: 24002-24007, 1997.[Abstract/Free Full Text]
  14. Ferreira A., Kosik K. S. Accelerated neuronal differentiation induced by p53 suppression. J. Cell Sci., 109: 1509-1516, 1996.[Abstract]
  15. Johnson J. E., Birren S. J., Anderson D. J. Two rat homologues of Drosophila achaete-scute specifically expressed in neuronal precursors. Nature (Lond.), 346: 858-861, 1990.[Medline]
  16. Lee J. E., Hollenberg S. M., Snider L., Turner D. L., Lipnick N., Weintrub H. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science (Washington DC), 268: 836-844, 1995.[Abstract/Free Full Text]
  17. Sasai Y., Kageyama R., Tagawa Y., Shigemoto R., Nakanishi S. Two mammalian helix-loop-helix factor structurally related to Drosophila hairy and Enhancer of split. Gene Dev., 6: 2620-2634, 1992.[Abstract/Free Full Text]
  18. Pevny L. H., Sockanathan S., Placzek M., Lovell-Badge R. A role for SOX1 in neuronal determination. Development (Camb.), 125: 1967-1978, 1998.[Abstract]
  19. Marvin M., McKay R. Multipotential stem cells in the vertebrate CNS. Semin. Cell Biol., 3: 401-411, 1992.[Medline]
  20. Frederiksen K., McKay R. D. G. Proliferation and differentiation of rat neuroepithelial precursor cells in vivo. J. Neurosci., 8: 1144-1151, 1998.[Abstract]
  21. Gage F. H., Coates P. W., Palmer T. D., Kuhn H. G., Fisher L. J., Suhonen J. O., Peterson D. A., Suhr S. T., Ray J. Proc. Natl. Acad. Sci. USA, 92: 11879-11883, 1995.[Abstract/Free Full Text]
  22. Lendahl U., Zimmerman L. B., McKay R. D. G. CNS stem cells express a new class of intermediate filament protein. Cell, 60: 585-595, 1990.[Medline]
  23. Josephson R., Muller T., Pickel J., Okabe S., Reynolds K., Tuner P. A., Zimmer A., McKay R. D. POU transcription factors control expression of CNS stem cell-specific genes. Development (Camb.), 125: 3087-3100, 1998.[Abstract]
  24. Debus E., Weber K., Osborn M. Monoclonal antibodies specific for glial fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides. Differentiation, 25: 193-203, 1983.[Medline]
  25. Dotti C. G., Banker G. A., Binder L. I. The expression of and distribution of the microtubule-associated tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture. Neuroscience, 23: 121-130, 1987.[Medline]
  26. Nagashima Y., Miyagi Y., Udagawa K., Taki A., Misugi K., Sakai N., Kondo K., Kaneko S., Yao M., Shuin T. von Hippel-Lindau tumor suppressor gene. Localization of the expression by in situ hybridization. J. Pathol., 180: 271-274, 1996.[Medline]
  27. Meltzer H., Hatton J. D., U H. S. Cell type-specific development of rodent central nervous system progenitor cells in culture. J. Neurosurg., 88: 93-98, 1998.[Medline]
  28. Sakashita N., Takeya M., Kishida T., Stackhouse T. M., Zbar B., Takahashi K. Expression of von Hippel-Lindau protein in normal and pathological human tissues. Histochem. J., 31: 133-144, 1999.[Medline]
  29. Kanno H., Hattori S., Sato H., Murata H., Huang F-H., Hayashi A., Suzuki N., Yamamoto I., Kawamoto S., Minami M., Miyatake S., Shuin T., Kaplitt M. G. Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-{gamma}. Cancer Gene Ther., 6: 147-154, 1999.[Medline]
  30. Ohtsuka T., Asahi M., Matsuura N., Kikuchi H., Hojo M., Kageyama R., Ohkubo H., Hoshimaru M. Regulated expression of basic helix-loop-helix transcription factors during differentiation of the immortalized neuronal progenitor cell line HC2S2 into neurons. Cell Tissue Res., 293: 23-29, 1998.[Medline]



This article has been cited by other articles:


Home page
 J. Physiol.Home page
N. Tajima, K. Schonherr, S. Niedling, M. Kaatz, H. Kanno, R. Schonherr, and S. H. Heinemann
Ca2+-activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1{alpha} and the von Hippel-Lindau protein
J. Physiol., March 1, 2006; 571(2): 349 - 359.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Tzouanacou, S. Tweedie, and V. Wilson
Identification of Jade1, a Gene Encoding a PHD Zinc Finger Protein, in a Gene Trap Mutagenesis Screen for Genes Involved in Anteroposterior Axis Development
Mol. Cell. Biol., December 1, 2003; 23(23): 8553 - 8552.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Ma, L. Tessarollo, S.-B. Hong, M. Baba, E. Southon, T. C. Back, S. Spence, C. G. Lobe, N. Sharma, G. W. Maher, et al.
Hepatic Vascular Tumors, Angiectasis in Multiple Organs, and Impaired Spermatogenesis in Mice with Conditional Inactivation of the VHL Gene
Cancer Res., September 1, 2003; 63(17): 5320 - 5328.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Naranjo-Suarez, M. C. Castellanos, M. Alvarez-Tejado, A. Vara, M. O. Landazuri, and L. del Peso
Down-regulation of Hypoxia-inducible Factor-2 in PC12 Cells by Nerve Growth Factor Stimulation
J. Biol. Chem., August 22, 2003; 278(34): 31895 - 31901.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Murata, N. Tajima, Y. Nagashima, M. Yao, M. Baba, M. Goto, S. Kawamoto, I. Yamamoto, K. Okuda, and H. Kanno
Von Hippel-Lindau Tumor Suppressor Protein Transforms Human Neuroblastoma Cells into Functional Neuron-like Cells
Cancer Res., December 1, 2002; 62(23): 7004 - 7011.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanno, H.
Right arrow Articles by U, H.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanno, H.
Right arrow Articles by U, H.-S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online